Durvalumab
- Level
- Commodity
- Parent
- 51111700
- Below
- 0
- Links · KBLI
- 8
Definition
UNSPSC 51111780Durvalumab is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[5] It is a human immunoglobulin G1 kappa (IgG1?) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).
Same parent
Under 51111700 · 67Activities that produce or sell this
KBLI · 8Inherited from family 51110000.
Warning
The links were generated with a large language model (Gemini 3.5 Flash), matching UNSPSC at the family level to KBLI at the kelompok level. Some of them maybe are wrong, so check any link you intend to rely on.